Amarin Corporation plc (NASDAQ: AMRN) has introduced what it calls a go-to-market strategy to spike the growth of VASCEPA® (Icosapent Ethyl) in the U.S.
The aim is to make sure patients can access to VASCEPA
With the new Go-to-Market approach, Amarin Corporation plc is hopeful that many patents are numbering into millions who would otherwise remain untreated gain access to VASCEPA. The company aims to reach out to several chunks of patients and help them.
There is a shift in the way physicians prefer to engage.
All efforts that are taken by Amarin Corporation plc are to make sure that both the medical professionals and patients benefit. Aaron Berg, executive vice president, and president U.S., of the company, shared that the newly introduced go-to-market strategy is robust and efficient in educating healthcare experts and patients about products that the group has introduced to minimize the risk of cardiovascular diseases and disorders. Berg is optimistic that the newly launched strategy will help Amarin Corporation plc spike VASCEPA prescription growth, resulting in an increasingly thriving and profitable franchise in the U.S.
The focus will be on the most productive territories in the U.S. markets
Under this model, the corporate house will focus on the most thriving and productive territories in the U.S. markets. By doing so, the group will reduce its U.S. field force to the nearly 300 sales representatives who will play a vital role in the company’s commercial strategy going ahead. Meanwhile, it has come to light that the company will continue to work near its payers to keep up the strong managed care position that it has built. The corporate house will also work on eliminating hurdles of the VASCEPA prescription and making sure that patients at risk of cardiovascular diseases and disorders receive the right therapy at the right time. Branded VASCEPA is currently the only medical solution that has received the U.S. Food and Drug Administration (FDA) approval that can be used in IPE medication for reducing the risk of cardiovascular diseases. In addition, it has come to light the group is analyzing several innovative solutions that are designed and developed to deal with IPE prescriptions for cardiovascular risk reduction.
Despite the advancement in diagnosing, treating, and managing cardiovascular disease, it remains the number one reason for mortality globally.
